DAWN
Beacon’s rare eye disease gene therapy signals vision function improvements in early phase 2 data
XLRP, gene therapy, laru-zova, visual function, rare eye disease, Phase 2 trial, DAWN trial, vision improvement, low light vision
Actionable Insights Powered by AI
XLRP, gene therapy, laru-zova, visual function, rare eye disease, Phase 2 trial, DAWN trial, vision improvement, low light vision